论文部分内容阅读
目的 :探讨肝硬化患者血浆尿激酶受体 (UPAR)含量的临床意义。方法 :应用酶联免疫吸附试验 (EL ISA)检测 2 0例健康成年人 ,6 3例肝硬化患者血浆 UPAR含量 (ng/ m l) ,其中肝硬化又分为三组 :肝硬化无腹水组 35例 ,肝硬化腹水组 1 8例 ,肝硬化腹水并发自发性腹膜炎 (spontaneous bacterial peritonitis,SBP)组 1 0例。半年后随访。结果 :1正常对照组 U PAR含量 1 .6 3± 0 .96 ng/ ml。 2肝硬化无腹水组 U PAR含量 2 .6± 1 .5 ng/ ml。两者比较无统计学意义 (P>0 .0 5 )。 3肝硬化腹水组UPAR含量 4 .5± 2 .3ng/ ml。 4 SBP组 UPAR含量 7.6± 5 .6 ng/ ml。肝硬化无腹水组、肝硬化腹水组、SBP组两两相比有显著差异 P<0 .0 1。且后两组肝硬化患者 U PAR含量均高于正常对照组 ,并且有显著差异 ,P<0 .0 1。而四组 UPAR含量有如下规律 :SBP组 UPAR含量 >肝硬化腹水组 >肝硬化无腹水组和正常对照组。结论 :所有肝硬化组的 U PAR含量均明显高于正常对照组 ,P<0 .0 1。我们认为 ,这可能与其病程发展进程中 ,由于肝组织的病变、损伤、坏死、炎症发生 ,同时正常的肝组织也代偿性增生有关。因此 ,我们认为 ,检测肝硬化患者血浆中 UPAR含量对患者病情的判断及发展方向有较高的临床价值
Objective: To investigate the clinical significance of plasma urokinase receptor (UPAR) in patients with liver cirrhosis. Methods: The levels of plasma UPAR (ng / ml) in 20 healthy adults and 63 cirrhotic patients were detected by enzyme-linked immunosorbent assay (ELISA). Liver cirrhosis was divided into three groups: cirrhosis without ascites 35 Cases, cirrhosis ascites group 18 cases of cirrhosis and spontaneous bacterial peritonitis (spontaneous bacterial peritonitis SBP) group of 10 cases. Follow-up after six months. Results: 1 The normal control group U PAR content 1.63 ± 0.96 ng / ml. 2 Liver cirrhosis without ascites U PAR content 2.6 ± 1.5 ng / ml. There was no significant difference between the two groups (P> 0.05). 3 UPAR content in cirrhotic ascites group 4.5 ± 2 .3ng / ml. 4 SBP group UPAR content of 7.6 ± 5 .6 ng / ml. Cirrhosis without ascites group, liver cirrhosis group, SBP group, any significant difference between two groups P <0. UPAR levels in the latter two groups of patients with cirrhosis were higher than those in the normal control group, and there was a significant difference (P <0.01). The UPAR content of the four groups had the following rules: UPAR content in SBP group> cirrhosis ascites group> cirrhosis without ascites group and normal control group. Conclusion: The levels of U PAR in all cirrhosis patients were significantly higher than those in normal controls (P <0.01). In our opinion, this may be related to the process of its development, due to liver tissue lesions, injuries, necrosis, inflammation, normal liver tissue also compensatory proliferation. Therefore, we believe that the detection of UPAR in the plasma of patients with cirrhosis has a high clinical value in judging and developing the patient’s condition